Story perspectives

Novartis pays $575 million for ABO2203 mRNA rights

By Drooid · Oct 2, 2026, 10:25 PM UTC · How we work

Summary

Story summary

Novartis signed a licensing deal with China's Abogen Biosciences for the mRNA therapy ABO2203.
Novartis will pay $575 million upfront for exclusive worldwide rights to ABO2203.
The agreement could total about $7.8 billion, including up to $7.2 billion in milestone payments.
Early human data showed sustained remission in refractory immune thrombocytopenia without cytokine release syndrome.

History

Historical Context

In 2010, Pfizer and German biotech BioNTech signed a $100 million licensing deal to develop mRNA influenza vaccines, the first major Western-Asian partnership on the technology. Novartis now offers Chinese firm Abogen Biosciences $575 million upfront for exclusive worldwide rights to its ABO2203 mRNA therapy, with potential milestones reaching $7.8 billion. Just as the 2010 Pfizer-BioNTech pact opened pathways for large-scale mRNA collaborations, Novartis’s 2024 deal mirrors that model, scaling cross-border investment and risk sharing. The precedent suggests that such multi-billion agreements could accelerate global therapeutic pipelines, prompting regulators like the FDA and WHO to adapt approval frameworks.

1 of 2

Story summary

Novartis signed a licensing deal with China's Abogen Biosciences for the mRNA therapy ABO2203.
Novartis will pay $575 million upfront for exclusive worldwide rights to ABO2203.
The agreement could total about $7.8 billion, including up to $7.2 billion in milestone payments.
Early human data showed sustained remission in refractory immune thrombocytopenia without cytokine release syndrome.

1 / 2